Salveen Richter, an analyst from Goldman Sachs, maintained the Buy rating on Biogen (BIIB – Research Report). The associated price target remains the same with $196.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Salveen Richter has given his Buy rating due to a combination of factors that highlight Biogen’s strategic initiatives and growth potential. The company is actively reallocating resources from its established multiple sclerosis segment to support new product launches, optimize its cost structure, and advance its late-stage programs. This approach is complemented by efforts to strengthen its early-stage pipeline through business development, focusing on both medium and long-term growth opportunities.
Additionally, Biogen’s strategy includes diversifying its portfolio with a focus on rare diseases and immunology, leveraging its existing expertise. The approval of a blood-based biomarker for Leqembi and the potential for broader reimbursement and physician adoption are seen as positive developments. Furthermore, the company’s pipeline includes promising assets in areas such as lupus and immune-mediated diseases, with significant data reads expected in the coming years. These strategic moves, along with Biogen’s strong US manufacturing presence and pricing strategies, underpin the Buy rating.
Richter covers the Healthcare sector, focusing on stocks such as Biogen, Amgen, and Regeneron. According to TipRanks, Richter has an average return of 9.0% and a 43.10% success rate on recommended stocks.